GLP1R and kidney disorder: This entwinement of kidney disease and metabolic syndrome complicates investigations with GLP-1 therapies due to the indirect benefits GLP-1R agonist therapies have on other tissues including but not limited to alterations in BP, glucose homeostasis, weight loss and insulin levels [reviewed in (155, 156, 161, 163)].